Borderline resectable esophageal cancer
Conditions
Interventions
Experimental group:Tislelizumab + nab-paclitaxel + cisplatin
Sponsors
Taizhou Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent; 2. Patients with diagnosed resectable or marginally resectable esophageal squamous cell carcinoma; 3. Patients with advanced disease who have not received systemic treatment before; 4. Aged 18 to 75 years; 5. The expected survival period is more than 6 months; 6. White blood cells>=4.0x10^9/l, neutrophils>=1.5x10^9/l, platelets>=100.0x10^9/l, hemoglobin>=90g/l; normal liver and kidney function; 7. ECOG PS 0~1 points.
Exclusion criteria
Exclusion criteria: 1. Patients who currently or have participated in any other anti-tumor clinical research; 2. Any previous treatment of esophageal cancer with systemic anticancer therapy as the main treatment method, including cytotoxic therapy, targeted therapy (including tyrosine kinase inhibitors or monoclonal antibodies) and immunotherapy, except for the use of neoadjuvant therapy ; 3. Patients who have received adjuvant therapy before enrollment; 4. Patients with stage III-IV esophageal cancer who do not receive the trial; 5. Female patients who are pregnant or breastfeeding; 6. Patients who are assessed by the investigator as unsuitable for enrollment, such as neurological disorders or metabolic disorders, physical examination or laboratory tests suspect the patient to have a possible disease, or have contraindications to the use of the study drug, or have treatment-related complications high risk etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient pathology assessment ;Patient imaging assessment;Evaluation standard of clinical efficacy after immunotherapy combined with chemotherapy; | — |
Countries
China
Contacts
Public ContactShen Jianfei
Taizhou Hospital
Outcome results
None listed